How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December

Lessons Learned from the World’s First Gene-Edited Babies

Why enforceable regulation and greater inclusion and diversity in global discourse are critical to effective management of gene editing Earlier this week, He Jiankui, a professor at China’s Southern University

New CRISPR Companies Heat Up as Skepticism Grows

Novel ways of harnessing CRISPR disrupt diagnostics, therapeutics, and food systems While much hype has been built around CRISPR-Cas9 and its ability to revolutionize treatment of genetic disorders and disease,

Think Twice Before Divesting CRISPR Amid Cancer Concerns

Why Headlines Linking CRISPR to Cancer are Misleading Investors Two papers published by Novartis and Karolinska Institute that warn of potential cancer risks associated with CRISPR-Cas9 editing sent share prices

Next-Gen Cancer Immunotherapy Biomarkers: Implications for Research Tools and Clinical Diagnostics

Our cancer immunotherapy biomarker database (I/O BioMAP) has now reached 1,000 clinical trials!  Having reached this milestone, we wanted to share some insights from our analysis of this data and

Immuno-Oncology Biomarkers: Landscape Summary 2017

Six years after the approval of the first checkpoint inhibitor, the explosion of research and development of cancer immunotherapies continues to accelerate at an unprecedented pace.  As a class, cancer

ASCO Musings: Diagnostics and Research Tools Takeaways from ASCO17

Chicago, IL June 6, 2017 – My colleague and I spent a few days wandering around the exhibit hall at ASCO17 and got to connect with many diagnostic and research

Talking Healthcare Analytics with Wout Brusselaers, CEO of Deep 6 AI

I recently had the pleasure to sit down with Wout Brusselaers, founder and CEO of South by Southwest Accelerator Pitch Event Winner Deep 6 AI, which at the time of

Diagnostic Biomarkers for Cancer Immunotherapy – Updated Jan. 2017

We continue to track the immuno-oncology (I/O) space closely and have recently made some updates to our prior analysis (here: of cancer immunotherapy biomarkers in clinical trials, adding >65